Posts by: Ines Martins, PhD

Ines Martins, PhD

Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.

March 20, 2019

EU Approves Keytruda/Chemo Combo to Treat Metastatic Squamous NSCLC

News

The European Commission has approved a combination of Keytruda (pembrolizumab) plus standard chemotherapy for the initial treatment of metastatic squamous non-small cell lung cancer (NSCLC), Merck (known as MSD ... Read more

March 8, 2019

Phase 3 Keytruda Trial Fails Primary Objectives in Liver Cancer Patients Who Received Prior Nexavar

News

Immune checkpoint inhibitor Keytruda (pembrolizumab) did not significantly improve the survival outcomes of previously treated hepatocellular carcinoma patients on best supportive care, results from a Phase 3 trial show. ... Read more

February 27, 2019

FDA Approves Keytruda for Melanoma Patients After Tumor Resection

News

The U.S. Food and Drug Administration has approved the use of Keytruda (pembrolizumab) as a treatment for melanoma patients with stage 3 disease — cancer cells have spread to the ... Read more

February 22, 2019

Keytruda Better Than Chemotherapy for Untreated Advanced Merkel Cell Carcinomas, Phase 2 Trial Suggests

News

Patients with an aggressive kind of skin cancer called Merkel cell carcinoma appear to have better responses and live longer when given the PD-1 inhibitor Keytruda (pembrolizumab), compared to ... Read more

February 20, 2019

FDA Grants Priority Review to Keytruda-Inlyta Combo for Untreated, Advanced Kidney Cancer Patients

News

The U.S. Food and Drug Administration has granted priority review to Merck‘s application requesting the approval of Keytruda (pembrolizumab) in combination with Inlyta (axitinib) for the initial treatment of ... Read more

February 12, 2019February 12, 2019

Bavencio Shows Promise in Phase 1 Trial of Heavily Treated Malignant Mesothelioma Patients

News

Immune checkpoint inhibitor Bavencio (avelumab) shows durable clinical activity and long-term disease control among heavily pretreated malignant mesothelioma patients, according to a Phase 1 clinical trial. The treatment — ... Read more

February 6, 2019February 6, 2019

FDA Expands Alimta’s Label for Initial Treatment of Metastatic Lung Cancer

News

The U.S. Food and Drug Administration has expanded Alimta‘s (pemetrexed) label to include a combination with Keytruda (pembrolizumab) and platinum chemotherapy for the initial treatment of certain metastatic non-small cell lung cancer (NSCLC) ... Read more

January 25, 2019January 25, 2019

Opdivo-Yervoy Combo Approved in Europe for First-line Treatment of Certain Kidney Cancers

News

The European Commission has approved a combination of Opdivo (nivolumab) and low-dose Yervoy (ipilimumab) for the initial treatment of advanced renal cell carcinoma patients with intermediate and poor risk, ... Read more

December 5, 2018December 5, 2018

Opdivo-Chemo Combo Doubles Survival Rates in Relapsed or Refractory Leukemia Patients, Phase 2 Trial Shows

News

A combination of Opdivo (nivolumab) and standard Vidaza (azacitidine) chemotherapy reduced the tumor burden in one-third of acute myeloid leukemia (AML) patients and doubled survival rates over patients treated with ... Read more

November 28, 2018

Opdivo Cancer Treatment Safe for HIV Patients on Antiretrovirals, Study Suggests

News

Patients with human immunodeficiency virus (HIV) may safely receive immune checkpoint inhibitors as a cancer treatment, as long as they continue taking antiretroviral therapies, a retrospective study shows. Findings ... Read more

Pin It on Pinterest